| niacin extended-release formulation / Generic mfg. |
2005-004080-28: Efficacy and Safety of Niaspan in South Asian Stroke Survivors: NIASTAR TRIAL(Niaspan: Indo-Asian Stroke patienT Atherosclerotic Regression trial) |
|
|
| Ongoing | 4 | 280 | Europe | Niaspan, Simvastatin, Niaspan, Simvastatin, Niaspan, Simvastatin | Sandwell Medical Research Unit | 1. Patients diagnosed as having a stroke based on the WHO CriteriaPatients with transient ischaemic attacks will be included if symptoms of motor or sensory loss were demonstrable with full recovery within 24 hours. Only strokes and TIA that are ischaemic in nature (thrombo-embolic) will be included in the study | | | | |
2005-002982-35: The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease |
|
|
| Ongoing | 4 | 40 | Europe | Niaspan, Phosex, Niaspan, PL 14994/0001, Niaspan, Phosex, Niaspan, Phosex | Barts and The London NHS Trust | Chronic renal failure (CKD stages 4 &%) | | | | |
2005-005347-25: Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV |
|
|
| Ongoing | 4 | 130 | Europe | Niaspan, Niaspan | Johannes Gutenberg-Universität Mainz, II. Med. Klinik (ausführende Stelle), Prof. Dr. med. T. Münzel | Women or men > 35 and < 80 years of age with a documented, clinically stable coronary artery disease (CAD) and a flow-mediated vasodilatation (FMD) of less than 8% from the heart catheter register of the department of medicine II, Johannes Gutenberg-University Mainz. | | | | |
2007-000197-24: EFFECTS OF NICOTINIC ACID PLUS SIMVASTATIN VS.SIMVASTATIN ALONE ON CAROTID AND FEMORAL INTIMA-MEDIA THICKNESS IN PATIENTS WITH PERIPHERAL ARTERY DISEASE (NASCIT) –A RANDOMIZED CONTROLLED TRIAL |
|
|
| Ongoing | 4 | 200 | Europe | Simvastatin Merck 40mg, Niaspan 500mg, Simvastatin Merck 40mg 1-24892, Niaspan 500mg Merck 1-25383, Simvastatin Merck 40mg 1-24892, Niaspan 500mg Merck 1-25383 | MUW, Univ.Klinik f. Innere Medizin II, Abteilung f. Angiologie | 200 consecutive patients with PAD and low serum HDL cholesterol levels (<45mg/dL in men, <55 mg/dL in women) will be enrolled in this single-center prospective randomized controlled open-label trial. | | | | |
2008-000465-37: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients. |
|
|
| | 3/4 | 200 | Europe | MK-0524A (ER-Niacin/Laropiprant) 1g/20mg, MK-0524A (ER-Niacin/Laropiprant) 1g/20mg, | Laboratoires Merck Sharp & Dohme - Chibret, Merck Sharp & Dohme GmbH, Merck Sharp & Dohme de España, S.A., MSD BV | Dyslipidemia | | 07/08 | | |
